Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report issued on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm lowered their price target on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, September 23rd.

Aptevo Therapeutics Stock Performance

Shares of Aptevo Therapeutics stock opened at $0.25 on Tuesday. Aptevo Therapeutics has a 12-month low of $0.14 and a 12-month high of $15.14. The firm’s 50 day simple moving average is $0.26 and its two-hundred day simple moving average is $0.55.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, beating the consensus estimate of ($1.93) by $0.26. Sell-side analysts anticipate that Aptevo Therapeutics will post -2.97 earnings per share for the current year.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics as of its most recent filing with the Securities & Exchange Commission. 8.06% of the stock is owned by hedge funds and other institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.